Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Checkpoint Inhibitors for Treating Cancer market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Checkpoint Inhibitors for Treating Cancermarket, defines the market attractiveness level of Checkpoint Inhibitors for Treating Cancer market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Checkpoint Inhibitors for Treating Cancer industry, describes the types of Checkpoint Inhibitors for Treating Cancer market, the applications of major players and the market size, and deeply analyzes the current situation of the global Checkpoint Inhibitors for Treating Cancer market and the development prospects and opportunities of Checkpoint Inhibitors for Treating Cancer industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Checkpoint Inhibitors for Treating Cancer market in Chapter 13.
By Player:
Bristol-Myers Squibb(BMS)
Merck
Roche
By Type:
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
By End-User:
CTLA-4 Inhibitors
CTLA-4 Inhibitors
CTLA-4 Inhibitors
CTLA-4 Inhibitors
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Checkpoint Inhibitors for Treating Cancer Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Checkpoint Inhibitors for Treating Cancer Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Checkpoint Inhibitors for Treating Cancer Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Checkpoint Inhibitors for Treating Cancer Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Checkpoint Inhibitors for Treating Cancer Market Analysis and Outlook to 2022
-
7.1 Global Checkpoint Inhibitors for Treating Cancer Consumption (2017-2022)
-
7.2 United States Checkpoint Inhibitors for Treating Cancer Consumption (2017-2022)
-
7.3 Europe Checkpoint Inhibitors for Treating Cancer Consumption (2017-2022)
-
7.4 China Checkpoint Inhibitors for Treating Cancer Consumption (2017-2022)
-
7.5 Japan Checkpoint Inhibitors for Treating Cancer Consumption (2017-2022)
-
7.6 India Checkpoint Inhibitors for Treating Cancer Consumption (2017-2022)
-
7.7 South Korea Checkpoint Inhibitors for Treating Cancer Consumption (2017-2022)
8 Region and Country-wise Checkpoint Inhibitors for Treating Cancer Market Analysis and Outlook to 2028
-
8.1 Global Checkpoint Inhibitors for Treating Cancer Consumption Forecast (2022-2028)
-
8.2 United States Checkpoint Inhibitors for Treating Cancer Consumption Forecast (2022-2028)
-
8.3 Europe Checkpoint Inhibitors for Treating Cancer Consumption Forecast (2022-2028)
-
8.4 China Checkpoint Inhibitors for Treating Cancer Consumption Forecast (2022-2028)
-
8.5 Japan Checkpoint Inhibitors for Treating Cancer Consumption Forecast (2022-2028)
-
8.6 India Checkpoint Inhibitors for Treating Cancer Consumption Forecast (2022-2028)
-
8.7 South Korea Checkpoint Inhibitors for Treating Cancer Consumption Forecast (2022-2028)
9 Global Checkpoint Inhibitors for Treating Cancer Market Outlook by Types and Applications to 2022
-
9.1 Global Checkpoint Inhibitors for Treating Cancer Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global PD-1 Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.2 Global PD-L1 Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.3 Global CTLA-4 Inhibitors Consumption and Growth Rate (2017-2022)
-
9.2 Global Checkpoint Inhibitors for Treating Cancer Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global CTLA-4 Inhibitors Consumption and Growth Rate (2017-2022)
-
9.2.2 Global CTLA-4 Inhibitors Consumption and Growth Rate (2017-2022)
-
9.2.3 Global CTLA-4 Inhibitors Consumption and Growth Rate (2017-2022)
-
9.2.4 Global CTLA-4 Inhibitors Consumption and Growth Rate (2017-2022)
10 Global Checkpoint Inhibitors for Treating Cancer Market Outlook by Types and Applications to 2028
-
10.1 Global Checkpoint Inhibitors for Treating Cancer Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global PD-1 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global PD-L1 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global CTLA-4 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Checkpoint Inhibitors for Treating Cancer Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global CTLA-4 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global CTLA-4 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global CTLA-4 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
10.2.4 Global CTLA-4 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
11 Global Checkpoint Inhibitors for Treating Cancer Import and Export Analysis (Top 5 Countries)
-
11.1 Global Checkpoint Inhibitors for Treating Cancer Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Checkpoint Inhibitors for Treating Cancer Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Checkpoint Inhibitors for Treating Cancer Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Checkpoint Inhibitors for Treating Cancer Market Competitive Analysis
-
14.1 Bristol-Myers Squibb(BMS)
-
14.1.1 Bristol-Myers Squibb(BMS) Company Details
-
14.1.2 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product and Service
-
14.2 Merck
-
14.2.1 Merck Company Details
-
14.2.2 Merck Checkpoint Inhibitors for Treating Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Merck Checkpoint Inhibitors for Treating Cancer Product and Service
-
14.3 Roche
-
14.3.1 Roche Company Details
-
14.3.2 Roche Checkpoint Inhibitors for Treating Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Roche Checkpoint Inhibitors for Treating Cancer Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Checkpoint Inhibitors for Treating Cancer
-
Figure Checkpoint Inhibitors for Treating Cancer Picture
-
Table Global Checkpoint Inhibitors for Treating Cancer Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Checkpoint Inhibitors for Treating Cancer Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Checkpoint Inhibitors for Treating Cancer Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Checkpoint Inhibitors for Treating Cancer Consumption by Country (2017-2022)
-
Figure United States Checkpoint Inhibitors for Treating Cancer Consumption and Growth Rate (2017-2022)
-
Table Europe Checkpoint Inhibitors for Treating Cancer Consumption and Growth Rate (2017-2022)
-
Figure China Checkpoint Inhibitors for Treating Cancer Consumption and Growth Rate (2017-2022)
-
Figure Japan Checkpoint Inhibitors for Treating Cancer Consumption and Growth Rate (2017-2022)
-
Figure India Checkpoint Inhibitors for Treating Cancer Consumption and Growth Rate (2017-2022)
-
Figure South Korea Checkpoint Inhibitors for Treating Cancer Consumption and Growth Rate (2017-2022)
-
Figure Global Checkpoint Inhibitors for Treating Cancer Consumption Forecast by Country (2022-2028)
-
Figure United States Checkpoint Inhibitors for Treating Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Checkpoint Inhibitors for Treating Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Checkpoint Inhibitors for Treating Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Checkpoint Inhibitors for Treating Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Checkpoint Inhibitors for Treating Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Checkpoint Inhibitors for Treating Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global PD-1 Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global PD-L1 Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global CTLA-4 Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global CTLA-4 Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global CTLA-4 Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global CTLA-4 Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global CTLA-4 Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global PD-1 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global PD-L1 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global CTLA-4 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global CTLA-4 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global CTLA-4 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global CTLA-4 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global CTLA-4 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Checkpoint Inhibitors for Treating Cancer Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Checkpoint Inhibitors for Treating Cancer Export by Region (Top 5 Countries) (2017-2028)
-
Table Bristol-Myers Squibb(BMS) (Foundation Year, Company Profile and etc.)
-
Table Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product and Service
-
Table Merck (Foundation Year, Company Profile and etc.)
-
Table Merck Checkpoint Inhibitors for Treating Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck Checkpoint Inhibitors for Treating Cancer Product and Service
-
Table Roche (Foundation Year, Company Profile and etc.)
-
Table Roche Checkpoint Inhibitors for Treating Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche Checkpoint Inhibitors for Treating Cancer Product and Service
-
